Answers are grounded in this paper and cite their sources.
Experiments demonstrate efficient cytosolic delivery of β-lactamase in macrophages, indicating AIP56's potential for targeted antigen therapies.
Introduction The intracellular delivery of biologics, particularly large cargoes like proteins, remains a challenge in biotechnology and biomedicine. The modular structure of well-characterized AB toxins allows different cargoes to be grafted, creating a target-specific biotechnological tool capable of cytosolic delivery. Methods In this study, we employed protein–protein fusion strategies—SpyCatcher003, SnoopCatcher, and SnoopLigase—to generate chimeras between the delivery region of AIP56 (AIP56 L258-N497 ) and β-lactamase and performed functional delivery assays. Results The chimeras were successfully obtained using these strategies and were all able to deliver β-lactamase into the cytosol of J774.A1 macrophages. Cellular fractionation showed that, although most of the β-lactamase remains associated with the endosomal compartment, an active portion is released into the cytosol. Conclusion AIP56 delivery region transporting other cargo directly to the cytosol of antigen-presenting cells might be a promising platform for antigen/cargo delivery. This study highlights the potential of protein–protein fusion strategies to create versatile, antigenically distinct toxin-based delivery systems for therapeutic applications.
No takes yet. Share an insight, caveat, or question.
Pinheiro et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: